No Prescription |
 |
 | ||
|
OXYSPAS Ditropan |
|
| ||
No Prescription » Prescription Drugs 12 » OXYSPAS Ditropan Oxybutynin is used to control urgent frequent or uncontrolled urination in people who have overactive bladder (a condition in which the bladder muscles have uncontrollable spasms) spina bifida (a disability that occurs when the spinal cord does not close properly before birth) or other conditions that affect the bladder muscles. Oxybutynin is in a class of medications called anticholinergics. It works by relaxing the bladder muscles to prevent urgent frequent or uncontrolled urination. Oxybutynin comes as a tablet a syrup and an extended-release (long-acting) tablet to take by mouth. The tablets and syrup are usually taken two to four times a day. The extended-release tablet is usually taken once a day with or without food. Take oxybutynin at around the same time(s) every day. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take oxybutynin exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Swallow the extended-release tablets whole with plenty of water or other liquid. Do not split chew or crush the extended-release tablets. Tell your doctor if you cannot swallow tablets.Your doctor may start you on a low dose of oxybutynin and gradually increase your dose not more than once every week.Oxybutynin may control your symptoms but will not cure your condition. Continue to take oxybutynin even if you feel well. Do not stop taking oxybutynin without talking to your doctor. Buy OXYSPAS Ditropan and other Prescription Drugs 12 products online at Medstore. Buy Online at Medstore - Click Here!
About OXYSPAS Ditropan: Product Type: Prescription Drugs 12 OXYSPAS ( Ditropan Generic Oxybutynin ) OXYSPAS (Ditropan Generic Oxybutynin) Ditropan Generic Oxybutynin 2.5mg Tabs Ditropan Generic Oxybutynin OXYSPAS
View more Prescription Drugs 12 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
